author-photo

Scott J. Jacober

Eli Lilly and Company
Wayne State University

76

Papers

3299

Citations

Citation Trend

Filter By

Papers (76) Sort By

Journal Conference Others

Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response

2018 Journal of diabetes science and technology
Show All
- Source
- Cite
- Save
Citations (2)
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

2018 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (5)
Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies:

2018 Journal of diabetes science and technology
Show All
- Source
- Cite
- Save
Citations (3)
Novel Hepato-Preferential Basal Insulin Peglispro (BIL) Does Not Differentially Affect Insulin Sensitivity Compared with Insulin Glargine in Patients with Type 1 and Type 2 Diabetes

2017 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins

2017 Journal of Investigative Medicine
Show All
- Source
- Cite
- Save
Citations (3)
CA-018: Enzymes hépatiques et contenu hépatique en graisse (CHG) – Résultats des essais cliniques de l'insuline Peligspro (BIL)

2016 Diabetes & Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction.

2016 The Journal of Clinical Endocrinology and Metabolism
Show All
- Source
- Cite
- Save
Citations (8)
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

2016 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (13)
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.

2016 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (21)
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.

2016 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (13)